364 related articles for article (PubMed ID: 19453251)
1. The posttranslational processing of prelamin A and disease.
Davies BS; Fong LG; Yang SH; Coffinier C; Young SG
Annu Rev Genomics Hum Genet; 2009; 10():153-74. PubMed ID: 19453251
[TBL] [Abstract][Full Text] [Related]
2. Prelamin A farnesylation and progeroid syndromes.
Young SG; Meta M; Yang SH; Fong LG
J Biol Chem; 2006 Dec; 281(52):39741-5. PubMed ID: 17090536
[TBL] [Abstract][Full Text] [Related]
3. Prelamin A, Zmpste24, misshapen cell nuclei, and progeria--new evidence suggesting that protein farnesylation could be important for disease pathogenesis.
Young SG; Fong LG; Michaelis S
J Lipid Res; 2005 Dec; 46(12):2531-58. PubMed ID: 16207929
[TBL] [Abstract][Full Text] [Related]
4. Blocking protein farnesylation improves nuclear shape abnormalities in keratinocytes of mice expressing the prelamin A variant in Hutchinson-Gilford progeria syndrome.
Wang Y; Ostlund C; Worman HJ
Nucleus; 2010; 1(5):432-9. PubMed ID: 21326826
[TBL] [Abstract][Full Text] [Related]
5. Absence of progeria-like disease phenotypes in knock-in mice expressing a non-farnesylated version of progerin.
Yang SH; Chang SY; Ren S; Wang Y; Andres DA; Spielmann HP; Fong LG; Young SG
Hum Mol Genet; 2011 Feb; 20(3):436-44. PubMed ID: 21088111
[TBL] [Abstract][Full Text] [Related]
6. Protein farnesyltransferase inhibitors and progeria.
Meta M; Yang SH; Bergo MO; Fong LG; Young SG
Trends Mol Med; 2006 Oct; 12(10):480-7. PubMed ID: 16942914
[TBL] [Abstract][Full Text] [Related]
7. An accumulation of non-farnesylated prelamin A causes cardiomyopathy but not progeria.
Davies BS; Barnes RH; Tu Y; Ren S; Andres DA; Spielmann HP; Lammerding J; Wang Y; Young SG; Fong LG
Hum Mol Genet; 2010 Jul; 19(13):2682-94. PubMed ID: 20421363
[TBL] [Abstract][Full Text] [Related]
8. N6-isopentenyladenosine improves nuclear shape in fibroblasts from humans with progeroid syndromes by inhibiting the farnesylation of prelamin A.
Bifulco M; D'Alessandro A; Paladino S; Malfitano AM; Notarnicola M; Caruso MG; Laezza C
FEBS J; 2013 Dec; 280(23):6223-32. PubMed ID: 24112551
[TBL] [Abstract][Full Text] [Related]
9. The farnesyl transferase inhibitor (FTI) lonafarnib improves nuclear morphology in ZMPSTE24-deficient fibroblasts from patients with the progeroid disorder MAD-B.
Odinammadu KO; Shilagardi K; Tuminelli K; Judge DP; Gordon LB; Michaelis S
Nucleus; 2023 Dec; 14(1):2288476. PubMed ID: 38050983
[TBL] [Abstract][Full Text] [Related]
10. New Lmna knock-in mice provide a molecular mechanism for the 'segmental aging' in Hutchinson-Gilford progeria syndrome.
Jung HJ; Tu Y; Yang SH; Tatar A; Nobumori C; Wu D; Young SG; Fong LG
Hum Mol Genet; 2014 Mar; 23(6):1506-15. PubMed ID: 24203701
[TBL] [Abstract][Full Text] [Related]
11. Blocking protein farnesyltransferase improves nuclear shape in fibroblasts from humans with progeroid syndromes.
Toth JI; Yang SH; Qiao X; Beigneux AP; Gelb MH; Moulson CL; Miner JH; Young SG; Fong LG
Proc Natl Acad Sci U S A; 2005 Sep; 102(36):12873-8. PubMed ID: 16129834
[TBL] [Abstract][Full Text] [Related]
12. Status of treatment strategies for Hutchinson-Gilford progeria syndrome with a focus on prelamin: A posttranslational modification.
Chen X; Yao H; Andrés V; Bergo MO; Kashif M
Basic Clin Pharmacol Toxicol; 2022 Oct; 131(4):217-223. PubMed ID: 35790078
[TBL] [Abstract][Full Text] [Related]
13. Blocking protein farnesyltransferase improves nuclear blebbing in mouse fibroblasts with a targeted Hutchinson-Gilford progeria syndrome mutation.
Yang SH; Bergo MO; Toth JI; Qiao X; Hu Y; Sandoval S; Meta M; Bendale P; Gelb MH; Young SG; Fong LG
Proc Natl Acad Sci U S A; 2005 Jul; 102(29):10291-6. PubMed ID: 16014412
[TBL] [Abstract][Full Text] [Related]
14. A-type lamins and Hutchinson-Gilford progeria syndrome: pathogenesis and therapy.
Gonzalez JM; Pla D; Perez-Sala D; Andres V
Front Biosci (Schol Ed); 2011 Jun; 3(3):1133-46. PubMed ID: 21622261
[TBL] [Abstract][Full Text] [Related]
15. [A-type lamins and progeroïd syndromes : persistent farnesylation with dramatic effects].
Navarro CL; Poitelon Y; Lévy N
Med Sci (Paris); 2008 Oct; 24(10):833-40. PubMed ID: 18950579
[TBL] [Abstract][Full Text] [Related]
16. Investigating the purpose of prelamin A processing.
Davies BS; Coffinier C; Yang SH; Barnes RH; Jung HJ; Young SG; Fong LG
Nucleus; 2011; 2(1):4-9. PubMed ID: 21647293
[TBL] [Abstract][Full Text] [Related]
17. Accumulation of distinct prelamin A variants in human diploid fibroblasts differentially affects cell homeostasis.
Candelario J; Borrego S; Reddy S; Comai L
Exp Cell Res; 2011 Feb; 317(3):319-29. PubMed ID: 20974128
[TBL] [Abstract][Full Text] [Related]
18. DNA damage responses in progeroid syndromes arise from defective maturation of prelamin A.
Liu Y; Rusinol A; Sinensky M; Wang Y; Zou Y
J Cell Sci; 2006 Nov; 119(Pt 22):4644-9. PubMed ID: 17062639
[TBL] [Abstract][Full Text] [Related]
19. Farnesyltransferase inhibitor and rapamycin correct aberrant genome organisation and decrease DNA damage respectively, in Hutchinson-Gilford progeria syndrome fibroblasts.
Bikkul MU; Clements CS; Godwin LS; Goldberg MW; Kill IR; Bridger JM
Biogerontology; 2018 Dec; 19(6):579-602. PubMed ID: 29907918
[TBL] [Abstract][Full Text] [Related]
20. Blocking farnesylation of the prelamin A variant in Hutchinson-Gilford progeria syndrome alters the distribution of A-type lamins.
Wang Y; Ostlund C; Choi JC; Swayne TC; Gundersen GG; Worman HJ
Nucleus; 2012; 3(5):452-62. PubMed ID: 22895092
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
